Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

The Intrinsic Apoptotic Pathway

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Beyond MURANO: sequencing therapy in relapsed chronic lymphocytic leukaemia.

Lancet (London, England)·2026

Same author

EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation.

HemaSphere·2026

Same author

Monocyte-mediated metabolic rewiring via CD31-CD38 interactions promotes growth and drug-resistance in multiple myeloma.

HemaSphere·2026

Same author

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.

Blood·2026

Same author

Censoring imbalances in randomized first-line trials of chronic lymphocytic leukemia.

Leukemia & lymphoma·2026

Same author

Humoral and cellular immune response after COVID-19 vaccination in patients with sickle cell disease on hydroxyurea.

Blood advances·2026

Search research articles

Related Experiment Video

Updated: Mar 13, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

TP53 dysfunction in CLL: Implications for prognosis and treatment.

Gera D Te Raa¹, Arnon P Kater²

¹Department of Hematology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Best Practice & Research. Clinical Haematology

|October 16, 2016

Summary

TP53 defects are a major negative prognostic factor in chronic lymphocytic leukemia (CLL), impacting treatment response. Current therapies are limited, highlighting the need for novel strategies beyond stem cell transplantation for TP53-defective CLL.

Keywords:

17p deletion ATM BCR kinase inhibitors CLL TP53 Venetoclax

More Related Videos

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Published on: October 23, 2019

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

Related Experiment Videos

Last Updated: Mar 13, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Published on: October 23, 2019

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

Area of Science:

Hematology
Oncology
Molecular Biology

Background:

TP53 defects are the primary adverse prognostic factor in chronic lymphocytic leukemia (CLL).
The incidence of TP53 defects increases with disease progression and relapse.
Standard detection methods like FISH for 17p deletion are crucial before initiating treatment.

Purpose of the Study:

To review the biological and clinical implications of TP53 dysfunction in CLL.
To evaluate current and emerging methods for detecting TP53 defects.
To discuss novel therapeutic strategies for TP53-defective CLL patients.

Main Methods:

Review of existing literature on TP53 defects in CLL.
Analysis of diagnostic techniques including FISH, NGS, and functional assays.
Discussion of treatment outcomes with targeted agents and immunochemotherapy.

Main Results:

TP53 defects significantly worsen outcomes with immunochemotherapy and affect responses to kinase inhibitors.
Novel agents like BCR-targeting drugs and Bcl-2 inhibitors show promise but require long-term follow-up.
Allogeneic stem cell transplantation remains the only curative option for TP53-defective CLL.

Conclusions:

Effective detection of TP53 defects is critical for treatment decisions in CLL.
Exploring rational combinations of targeted agents is essential for improving outcomes in TP53-defective CLL.
Further research into novel therapeutic strategies is needed for this high-risk patient group.